Clinical Trial Update: Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating HBI-8000 plus nivolumab versus placebo plus nivolumab in advanced unresectable or metastatic melanoma, including patients with pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• HBI-8000
• nivolumab (nivolumab)

Snippet

Sponsor: HUYABIO International, LLC. | Conditions: Unresectable or Metastatic Melanoma, Progressive Brain Metastasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING